Radotinib Completed Phase 3 Trials for Myeloid Leukemias / Philadelphia Chromosome / Bone Marrow Diseases / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Hematologic Diseases / Leukemias Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT01511289Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients